Tocilizumab for the treatment of rheumatoid arthritis
National Institute for Health and Clinical Excellence
Record ID 32011000067
English
Authors' recommendations:
1.1 Tocilizumab, in combination with methotrexate, is recommended for the treatment of moderate to severe active rheumatoid arthritis in people whose rheumatoid arthritis has responded inadequately to one or more tumour necrosis factor alpha (TNF-α) inhibitors and:• whose rheumatoid arthritis has responded inadequately to rituximab or• in whom rituximab is contraindicated or when rituximab is withdrawn because of an adverse effect.1.2 People who are currently receiving tocilizumab for the treatment of rheumatoid arthritis and whose circumstances do not meet the criteria described in 1.1 should have the option to continue treatment until they and their clinicians consider it appropriate to stop.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.nice.org.uk/TA198
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England
MeSH Terms
- Antibodies, Monoclonal
- Antirheumatic Agents
- Methotrexate
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
<p>National Institute for Health and Clinical Excellence (NICE)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.